Skip to main content
Bristol Myers Squibb10-Q: Compliance burden

HHS selects Orencia for negotiated government-set prices beginning in 2028 under IRA

Source: Autobound Signal API · 118 signals tracked for Bristol Myers Squibb · updated

Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.

What happened

Under the Inflation Reduction Act, HHS announced maximum fair prices for Eliquis starting January 1, 2026, Pomalyst starting January 1, 2027, and selected Orencia in January 2026 for government-set pricing beginning in 2028. This regulatory mandate creates compliance and revenue-management pressure that may require specialized pharma pricing analytics software.

Source

SEC EDGARJul 30, 2026

Quarterly report (Form 10-Q)

Bristol Myers Squibb 10-Q for Quarter ended Jun 30, 2026

Filing excerpt

Under the IRA, the HHS announced the "maximum fair price" for a 30-day equivalent supply of Eliquis, which applies to the U.S. Medicare channel effective January 1, 2026 and the "maximum fair price" for a 30-day supply of Pomalyst, which applies to the U.S. Medicare channel effective January 1, 2027. Additionally, in January 2026, the HHS selected Orencia as a medicine subject to "negotiation" for government-set prices beginning in 2028.

sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htmRead the full source

Other signals in this filing (1)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Compliance burden

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Jun 30, 2026
Fiscal year end
06/30
Filed
Jul 30, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
14272
Accession number
0000014272-26-000020
Timeframe
Multi year
Quarter
Q2
Filing year
2026
Period end date
Jun 30, 2026
Why it matters
GRC tools needed
Signal category
Risk

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
75%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
complianceBurden

Use this data

Get every 10-Q signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/d29dce02-dc7e-4899-b8e4-694bdc6728c2 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.

{
  "signal_id": "d29dce02-dc7e-4899-b8e4-694bdc6728c2",
  "signal_type": "sec-10q",
  "signal_subtype": "complianceBurden",
  "detected_at": "2026-11-09T06:30:46.35+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "detail": "Under the Inflation Reduction Act, HHS announced maximum fair prices for Eliquis starting January 1, 2026, Pomalyst starting January 1, 2027, and selected Orencia in January 2026 for government-set pricing beginning in 2028. This regulatory mandate creates compliance and revenue-management pressure that may require specialized pharma pricing analytics software.",
    "metrics": {
      "timeframe": "multi_year"
    },
    "quarter": "Q2",
    "summary": "HHS selects Orencia for negotiated government-set prices beginning in 2028 under IRA",
    "excerpts": "Under the IRA, the HHS announced the \"maximum fair price\" for a 30-day equivalent supply of Eliquis, which applies to the U.S. Medicare channel effective January 1, 2026 and the \"maximum fair price\" for a 30-day supply of Pomalyst, which applies to the U.S. Medicare channel effective January 1, 2027. Additionally, in January 2026, the HHS selected Orencia as a medicine subject to \"negotiation\" for government-set prices beginning in 2028.",
    "relevance": 0.75,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm",
    "filing_date": "2026-07-30",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "06/30",
    "period_end_date": "2026-06-30",
    "sales_relevance": "GRC tools needed",
    "signal_category": "risk",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.